Context Therapeutics’ (CNTX) Buy Rating Reaffirmed at D. Boral Capital

Context Therapeutics (NASDAQ:CNTX)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a report released on Tuesday,Benzinga reports. They presently have a $9.00 price target on the stock.

CNTX has been the topic of several other reports. JMP Securities initiated coverage on Context Therapeutics in a research note on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Context Therapeutics in a research note on Friday, March 21st. Citizens Jmp upgraded shares of Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. Finally, William Blair initiated coverage on shares of Context Therapeutics in a research report on Monday, April 21st. They issued an “outperform” rating on the stock. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Context Therapeutics presently has a consensus rating of “Buy” and an average target price of $6.17.

Context Therapeutics Stock Performance

CNTX opened at $0.87 on Tuesday. Context Therapeutics has a fifty-two week low of $0.55 and a fifty-two week high of $2.75. The firm has a 50-day moving average of $0.78 and a 200 day moving average of $1.18. The firm has a market cap of $77.77 million, a P/E ratio of -0.95 and a beta of 2.18.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. Equities research analysts predict that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

Several hedge funds have recently bought and sold shares of the company. Jane Street Group LLC bought a new position in Context Therapeutics in the 4th quarter valued at $29,000. Citadel Advisors LLC purchased a new stake in shares of Context Therapeutics in the fourth quarter worth $31,000. Shay Capital LLC bought a new stake in Context Therapeutics during the fourth quarter valued at $52,000. Clear Harbor Asset Management LLC grew its position in Context Therapeutics by 60.6% during the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock worth $61,000 after buying an additional 21,804 shares in the last quarter. Finally, Landscape Capital Management L.L.C. bought a new position in Context Therapeutics in the 4th quarter worth about $94,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.